Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
A legfontosabb adatok
- Ki végzi
- University of Zurich
- Hol
- Basel, Nottwil, Sion és Zurich (Svájc)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 114 fő, tervezett
- Kezdés
- 2019. jún. 19.
- Várható befejezés
- 2028. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- VERUM TTNS
- SHAM TTNS
- A regiszteradat frissítve
- 2026. november 5.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a recent spinal cord injury in the neck or upper back. It tests skin nerve stimulation at the ankle to prevent an overactive bladder.
- Életkor
- Over 18 years
- Nem
- All
- A betegség stádiuma
- Acute spinal cord injury at cervical (neck) or thoracic (upper back) level, within 40 days after injury. Traumatic injury, or non-traumatic injury that came on suddenly (<7 days).
- Korábbi kezelés
- Cannot join after treatment with antimuscarinics or mirabegron. No bladder or bowel neuromodulation in the last six months or ongoing. No Botulinum toxin injections in the bladder muscle or urethral sphincter in the last six months. During the study, no PTNS, no FES apart from upper limb FES, and no EMS.
- Biomarker vagy leletérték
- Cannot join if the tibial nerve muscle response (cMAP) is missing on both sides (amplitude < 1mV). Cannot join if bladder contractions are greater than 40 cmH2O at a filling volume of less than 500mL at the first visit.
A részvétel fő kizáró okai
- Other medical conditions that could cause safety problems, such as Parkinson's disease, multiple sclerosis, ALS or urological cancers
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Drug or alcohol abuse, or expected trouble following the study plan
- Being unable to follow study procedures, for example due to language problems, psychological disorders or dementia
- Being in another study with an investigational drug or product in the 30 days before or during this study
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Age >18 years
- Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI) within 40 days after injury
- Patients with acute SCI at cervical or thoracic level
- Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI); no percutaneous tibial nerve stimulation (PTNS); no functional electrical stimulation (FES), apart from upper limb FES; no electrical muscle stimulation (EMS)
- Informed Consent
Ki nem vehet részt
- Contraindications to the investigational product
- Treatment with antimuscarinics or with mirabegron
- Known or suspected non-adherence, drug or alcohol abuse
- Participation in another study with investigational drug or product within the 30 days preceding and during the present study
- Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
- Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
- Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
- Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Helyszínek itt: Svájc
- REHAB BaselBasel, SvájcContact: Sandra Möhr, pract. med.Résztvevőt keres
- Swiss Paraplegic CentreNottwil, SvájcContact: Jürgen Pannek, Prof. Dr. med.Résztvevőt keres
- Spinal Cord Injury Department, Clinique romande de réadaptionSion, SvájcContact: Xavier Jordan, Dr. med.Résztvevőt keres
- Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University HospitalZurich, SvájcContact: Thomas M Kessler, Prof. Dr. med.Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.
A teljes eredeti leírásKevesebb
This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.
Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.
A vizsgálat 2 csoportja
- VERUM transcutaneous tibial nerve stimulation (TTNS)A vizsgált kezelés
Kezelés: VERUM TTNS
- SHAM transcutaneous tibial nerve stimulation (TTNS)Színlelt kezelés, összehasonlításként
Kezelés: SHAM TTNS
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Transcutaneous Tibial Nerve Stimulation in Patients With Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: A Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- A regiszteradat frissítve
- 2026. november 5.